NIH scientists develop technique that provides new insight into stroke
NIH-funded study helps answer decades old question about emergency blood pressure management options
Small blood clots called emboli are mostly known for traveling through the vasculature before they lodge and obstruct vessels, impeding blood and oxygen supply to organs like the lung. To stop excessive bleeding or the flow of blood into an aneurysm, clinicians harness the same principle by forming artificial therapeutic emboli that can plug blood-carrying vessels. Using steerable catheters, they place tiny soft metal coils or liquid embolic agents ("glues") into the affected artery to block the passage of blood.
Although cerebral aneurysms affect a substantial portion of the adult population, the risk of treatment including open brain surgery often outweighs the risks associated with rupture. With increasing numbers of unruptured aneurysms detected using noninvasive imaging techniques, there is an urgent need for a reliable method to distinguish aneurysms vulnerable to impending rupture from those that are presently robust and can be safely monitored. An international research team led by the University of Pittsburgh Swanson School of Engineering recently received a grant from the National Institutes of Health (NIH) to improve risk assessment and treatment of this devastating disease.
A Louisville patient is the first to be enrolled in a national clinical trial to test a new treatment for patients who have suffered a ruptured brain aneurysm. The trial, based at the University of Louisville under principal investigator Robert F. James, M.D., associate professor in the Department of Neurosurgery at UofL, will include eight other medical centers in the United States.
Following the onset of a stroke, restoring blood flow to the brain as quickly as possible is critical for preventing disability and improving the chances of recovery. This crucial window for treatment is a narrow one - about 4 ½ hours - and the earlier the treatment, the better the outcome.
The University of Alabama at Birmingham has received a BRAIN Initiative grant of $7.3 million over five years from the National Institutes of Health to study new technology that could improve outcomes from deep brain stimulation, an increasingly important treatment for Parkinson´s disease and other movement disorders.
In a first of its kind study, Mount Sinai researchers are using optimal coherence tomography (OCT) angiography to look at the earliest stages of glaucoma and identify characteristic patterns of different forms of glaucoma based on their vascular patterns. The research could lead doctors to diagnose glaucoma cases earlier than ever before and potentially slow down the progression of vision loss.
Research from Mayo Clinic included in the November issue of JAMA Neurology identifies a new biomarker for brain and spinal cord inflammation, allowing for faster diagnosis and treatment of patients.
In the past 40 years, there has been a large increase in the number of people living with high blood pressure worldwide because of population growth and ageing—rising from 594 million in 1975 to over 1.1 billion in 2015.
A growing understanding of the highly "plastic," changeable nature of the brain--from the level of DNA, proteins, neuronal connections and networks, up to communication across brain regions--is driving the development of new therapeutic approaches to treat chronic pain, stroke, Parkinson´s disease, and a variety of other disorders described in an article in Alternative and Complementary Therapies, a journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Alternative and Complementary Therapies website until December 16, 2016.
Atrial fibrillation patients who use the drug, warfarin, to prevent harmful blood clots from forming in their hearts to lower risk of stroke are at higher risk of developing dementia than patients who use warfarin for non-atrial fibrillation conditions, according to a new study from the Intermountain Medical Center Heart Institute.
We are at the point of paradigm shift in treating stroke victims. High tech solutions are about to bring improvements that have been unthinkable. Bionik Laboratories is a pioneer in the field with a clear path to extraordinary growth.
Researchers from the San Francisco Veterans Affairs Medical Center and UCSF, and CalciMedica, Inc., are presenting a poster at the 46th annual Society for Neuroscience meeting in San Diego describing the use of calcium release-activated calcium (CRAC) channel inhibitors in traumatic brain injury (TBI). The poster, to be presented on Wednesday, November 16th, is titled "Calcium release-activated calcium (CRAC) channel inhibition protects against experiment brain injury by inhibiting microglial activation".
CLEVELAND, Oct. 17, 2016 -- (Healthcare Sales & Marketing Network) -- Synapse Biomedical Inc. (www.synapsebiomedical.com) announced that the results of a small French trial (RespiStimALS), designed to assess the NeuRx® Diaphragm Pacing System (DPS) in newly diagnosed ALS patients, were published in Lancet Neurology.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos